A recent comparative study reported talquetamab demonstrated superior efficacy compared with physician’s choice therapies in patients with relapsed multiple myeloma. The analysis, published in Advances in Therapeutics, evaluated response rates and clinical outcomes in heavily pretreated cohorts, underscoring talquetamab’s activity as a bispecific antibody targeting GPRC5D. Results add to growing clinical evidence supporting bispecifics as an alternative to existing salvage regimens, and could influence treatment sequencing and trial design for late-line myeloma. Sponsors and clinicians will consider durability, safety profile and real-world feasibility when integrating talquetamab into practice.